#### 1709

## FOUR-MONTH TREATMENT WITH NEW ANTIDIABETIC AGENTS (GLP-I/SGLT-2I) IMPROVES CARDIOVASCULAR FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ISCHEMIC STROKE

# V. Prentza<sup>1</sup>, <u>A. Kountouri<sup>1</sup></u>, I. Ikonomidis<sup>2</sup>, G. Pavlidis<sup>2</sup>, K. Katogiannis<sup>2</sup>, J. Thymis<sup>2</sup>, L. Pliouta<sup>1</sup>, E. Korakas<sup>1</sup>, G. Kostelli<sup>2</sup>, E. Mixalopoulou<sup>2</sup>, K. Balampanis<sup>1</sup>, L. Palaiodimou<sup>3</sup>, C. Zompola<sup>3</sup>, G. Tsivgoulis<sup>3</sup>, V. Lambadiari<sup>1</sup>

<sup>1</sup>Attikon University Hospital, Second Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece, <sup>2</sup>Attikon University Hospital, Second Cardiology Department, Laboratory of Preventive Cardiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, <sup>3</sup>Attikon University Hospital, Second department of Neurology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

**Background and aims:** Patients with type 2 diabetes mellitus(T2DM) and ischemic stroke present impaired markers of vascular and endothelial function. Glucagon-like peptide-1 receptor agonists(GLP-1) and sodium-glucose contrasporter-2 inhibitors(SGLT-2i) are novel antidiabetic agents reducing the risk of cardiovascular complications. We investigate the effect of treatment with GLP-1 or SGLT-2is on cardiovascular and endothelial function in patients with T2DM and ischemic stroke.

**Methods:** We recruited in total 81 patients with T2DM and ischemic stroke who received dulaglutide(n=27), dapagliflozin(n=27) or insulin(n=27). We measured at baseline and at four months post-treatment the: a)Carotid-femoral pulse wave velocity(PWV) b)Augmentation index(Aix) c)Central systolic blood pressure(cSBP) dPerfused boundary region(PBR) of the sublingual arterial microvessels and e) Left ventricular global longitudinal strain(GLS).

**Results:** At baseline, patients among the three groups had similar age, sex, HbA1c and markers of endothelial and cardiovascular function(p>0.05). After four months treatment, patients on dapagliflozin and on dulaglutide displayed a greater reduction of PWV(12.98 $\pm$ 3.23 vs.11.62 $\pm$ 1.74m/s,p=0.017, 14.77 $\pm$ 1.97 vs.13.59 $\pm$ 2.20m/s,p=0.042 respectively), of cSBP(132.15 $\pm$ 14.03vs.120.27 $\pm$ 10.05mmHg,p=0.035, 139 $\pm$ 7.25 vs.129 $\pm$ 7.75mmHg,p=0.045 respectively), of Aix(17.10 $\pm$ 17.83 vs 5.97 $\pm$ 28.99,p=0.028, 8.59 $\pm$ 20 vs 7.46 $\pm$ 6.36,p=0.039 respectively) and of GLS(-16.87 $\pm$ 3.28 vs -18.76 $\pm$ 3.35, p=0.001, -16.31 $\pm$ 3.42 vs -17.48 $\pm$ 3.14, p=0.004 respectively) compared to patients on insulin. PBR values were improved only in patients on dulaglutide(2.10 $\pm$ 0.16 vs 2.00 $\pm$ 0.14,p=0.025 vs dapagliflozin: 2.04 $\pm$ 0.23 vs 2.00 $\pm$ 0.11,p=0.696 vs insulin: 2.13 $\pm$ 0.3 vs 2.15 $\pm$ 0.3,p=0.567).

**Conclusions:** Dulaglutide and dapagliflozin improve cardiovascular function, but only dulaglutide improves endothelial glycocalyx in patients with T2DM and ischemic stroke after four months treatment. **Disclosure:** No

#### 1711

THE EFFECTIVENESS OF ADDITIONAL CORE STABILITY EXERCISES IN IMPROVING DYNAMIC SITTING BALANCE, COORDINATION AND LOWER LIMB SPASTICITY FOR SUBACUTE STROKE-SURVIVORS (CORE-TRIAL). A RANDOMIZED CONTROLLED TRIAL

#### <u>R. Cabanas-Valdés<sup>1</sup>,</u> L. Boix Sala<sup>2</sup>, J.A. Guzmán Bernal<sup>3</sup>, N. Torrella Vivó<sup>4</sup>, A.V. Lobato Bonilla<sup>5</sup>, S. González Hoelling<sup>6</sup>, B. Molina Hervas<sup>7</sup>, G. Urrútia<sup>8</sup>

<sup>1</sup>Universitat Internacional de Catalunya, Physical Therapy, Sant Cugat del Valles, Spain, <sup>2</sup>Hospital Universitari de Vic, Rehabilitation, Vic, Spain, <sup>3</sup>Germanes Hospitalaries Sagrat Cor, Rehabilitation, Martorell, Spain, <sup>4</sup>Hospital de Tarrassa, Rehabilitation, Terrassa, Spain, <sup>5</sup>Centre Fòrum | Consorci MAR Parc de Salut de Barcelona, Rehabilitation, Barcelona, Spain, <sup>6</sup>Hospital Sociosanitari Mutuam Girona, Rehabilitation, Girona, Spain, <sup>7</sup>Parc Taulí Hospital Universitari, Rehabilitation, Sabadell, Spain, <sup>8</sup>Centro Cochrane Iberoamericano - Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), CIBERESP, Public Health, Barcelona, Spain

**Background and aims:** Trunk impairment produces disorders of motor control, balance and gait in post-stroke survivors. Core stability exercises (CSE) are a good strategy to improve local strength of trunk but little information is available for acute phase of stroke individuals. Therefore the aim of this study is assess the effectiveness of CSE in subacute (< I month) stroke patients in addition to CP.

Methods and analysis: This is a two parallel group, single-blind, multicenter randomized controlled trial. All stroke survivors performed conventional physiotherapy (CP), active-assisted mobilizations, stretching and strength exercises of hemiparetic side, balance training and gait in parallel bars. Control group (CG) trained I hour of CP and EG performed 30 minutes of CSE and 30 minutes of CP during five days a week for five weeks in the first month post-stroke. Primary outcome measures were dynamic sitting balance, assessed by Spanish-Trunk Impairment Scale and Spanish-Function in Sitting Test and gait by Brunel Balance Assessment (stepping). Secondary outcomes were postural control (mobility and balance) assessed by Spanish-Postural Assessment Scale for Stroke, standing balance assessed by Berg Balance Scale and lower-limb spasticity by Modified Ashworth Scale, the degree of disability by modified Rankin Scale and activities of daily living by Barthel Index. The evaluators were blinded to intervention and individuals were measured at baseline and 5-week.Descriptive statistics have been used for the characterization of the sample. The mean value and standard deviation were calculated for continuous data in both groups and individuals characteristics were described using frequencies and percentages. Statistical analysis was performed with IBM SPSS Statistics software (Version 24). Paired T Test was used for comparison analysis with a significant level of 0.05.

**Results:** Eighty-seven individuals were evaluated, CG: 45 and EG:42. The groups were comparable at baseline (Table 1). Both groups improved after five weeks of treatment (Table 2). The lower limb modified Ashworth Scale score (Figure 1), dynamic sitting balance, coordination (Figure 2) and standing balance scores were statistical significant in favor EG (Table 3).

**Conclusions:** Twenty-five sessions of CSE in addition to conventional physiotherapy improve dynamic sitting balance, sitting coordination, standing balance and prevents lower-limb spasticity in subacute (< I month) stroke survivors with moderately severe disability.

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee Research of each hospital. It was funded by Fundació Marató TV3, grant number 201737-83. Protocol registration is in ClinicalTrials.gov number Identifier NCT03975985.

Variable	Scoring Range	Experimental Group (n=42)	Control Group (n=45)	P value*
Age		71.38 (11.789)	69.33 (15.331)	0.758
Gender (women/men)		12/30	18/27	0.296
BMI		26.56 (5.556)	27.51 (4.773)	0.425
Time post-stroke, days		25.12 (17.3)	21.37 (16)	0.225
Paretic side, (left/right)		20/22	26/19	0.286
Type of stroke, ischemic/hemorrhagic		35/7	37/8	0.891
Thrombectomy/thrombolysis		2/2	6/1	0.317
NIHSS stroke severity	0-42	8.02 (4.297)	7.04 (4.226)	0.287
Physical activity (previously)		19 (50.0%)	21 (42.2%)	0.467
Falls (previously)		2 (4.8%)	4 (8,9%)	0.448
Primary outcome measure				
S-TIS dynamic sitting balance	0-10	3.38 (2.837)	3.69 (2.575)	0.597
S-TIS coordination	0-6	1.45 (1.131)	1.89 (1.434)	0.120
S-TIS total	0-16	4.83 (3.449)	5.58 (3.230)	0.301
BBA stepping section	0-6	1.175 (1.893)	1.56 (2.323)	0.416
Secondary outcome measure				
Barthel Index	0-100	42.44 (25.449)	44.33 (27.810)	0.743
Berg Balance Scale	0-56	21.20 (18.236)	23.89 (19.010)	0.505
S-Function in Sitting Test	0-56	44.38 (15.611)	43.29 (18.299)	0.767
Modified Ashworth Scale	0-4	0.56 (0.812)	0.58 (0.923)	0.929
Modified Rankin Scale	0-6	3.98 (1.000)	3.91 (1.151)	0.863
S-PASS mobility	0-21	14.15 (5.734)	14.82 (5.086)	0.564
S-PASS balance	0-15	6.71 (3.600)	7.27 (3.875)	0.491
S-PASS (total)	0-36	20.36 (9.466)	22.09 (8.612)	0.374

#### Table I. Patients Characteristics at baseline (n=87).

Values are presented as mean and standard deviation (SD) or absolute frequency, \*p value < 0.05, the method of pairwise comparison was used. Abreviations: BBA: Brunel Balance Assessment, BMI: Body mass index, NIHSS: National Institutes of Health Stroke Scale, S-PASS: Spanish Postural Assessment Scale for Stroke, S-TIS: Spanish Trunk Impairment Scale 2.0.

#### Table 2. Post-treatment values.

Variable	Experimental Group (n=41)	P value <sup>*</sup>	Control Group (n=45)	P value*
Primary outcome measure				
S-TIS dynamic sitting balance	9.15 (2.338)	0.000*	6.35 (2.844)	0.000*
S-TIS coordination	4.22 (1.405)	0.000*	2.98 (2.773)	0.005*
S-TIS total	13.53 (3.220)	0.000*	9.95 (4.460)	0.000*
BBA stepping section	3.05 (2.207)	0.000*	2.84 (2.339)	0.000*
Secondary outcome measure				
Barthel Index	64.74 (26.609)	0.000*	66.98 (27.258)	0.000*
BBS	35.70 (20.081)	0.000*	35.49 (17.957)	0.000*
S-Function in Sitting Test	48.93 (14.083)	0.004*	50.05 (11.598)	0.000*
Modified Ashworth Scale	0.48 (0.640)	1.000	1.05 (1.154)	0.003*
Modified Rankin Scale	3.27 (1.062)	0.000*	3.28 (1.076)	0.000*
S-PASS mobility	18.30 (4.847)	0.000*	17.81 (4.398)	0.000*
S-PASS balance	9.93 (3.377)	0.000*	9.23 (3.689)	0.000*
S-PASS total	28.23 (7.830)	0.000*	27.05 (7.734)	0.000*


Abreviations: BBA: Brunel Balance Assessment, S-PASS: Spanish Postural Assessment Scale for Stroke, S-TIS 2.0: Spanish Trunk Impairment Scale 2.0. Values are presented as mean and standard deviation (SD) \*p value < 0.05.

Table 3.	Comparison	between	experimental	and control	groups c	oost-treatment.
			er p er innenteau		8. 0 m P F	

Variable	Mean difference standard error	P value*	
Primary outcome measure			
S-TIS dynamic sitting balance	2.801 (0.574)	0.000*	
S-TIS coordination	1.248 (0.488)	0.012*	
S-TIS total	3.578 (0.901)	0.000*	
BBA stepping section	0.213 (0.500)	0.672	
Secondary outcome measure			
Barthel Index	2.240 (6.002)	0.710	
Berg Balance Scale	0.212 (4.176)	0.445	
S-Function in Sitting Test	1.122 (2.824)	0.692	
Modified Ashworth Scale	0.572 (0.207)	0.007*	
Modified Rankin Scale	0.004 (0.238)	0.769	
S-PASS mobility	0.486 (1.015)	0.258	
S-PASS balance	0.692 (0.778)	0.039*	
S-PASS total	1.178 (1.709)	0.095	

Abreviations: BBA: Brunel Balance Assessment, S-PASS: Spanish Postural Assessment Scale for Stroke, S-TIS 2.0: Spanish Trunk Impairment Scale 2.0.

\*p value < 0.05.



Pre\_Post

Figure 2: Spanish-Trunk Impairment Scale 2.0. Coordination subscale, experimental group (CORE) is better than control group (CTRL).

#### Disclosure: No

### 561